Abstract Nickel-compound engineered nanomaterials (Ni-X NP) have diverse applications, yet their continued use raises concerns for potential health impacts on exposure. This study investigated three structurally distinct Ni-X-NP –pure NiO (NCZ), NiO@Ni(OH)2 (SIG), and Ni@NiO@Ni(OH)2 (AA)–to determine how core composition and surface functionalization contribute to bioactivity. Each Ni-X NP was modified with surface moieties (-OH, -COOH, and -CH3) to assess efficacy of surface modifications reducing bioactivity. Ni-X NP were thoroughly characterized for structure, surface chemistry, and Ni2+ ion release in simulated lysosomal fluid. Red blood cells (RBC) were used to evaluate hemolytic capabilities of the nanoparticles and primary murine alveolar macrophages (AM) and cultured murine ex vivo alveolar macrophages (mexAM) were used to assess uptake, cytotoxicity, IL-1β release, and lysosomal membrane permeability (LMP). Results showed that NiO@Ni(OH)2 nanoparticles induced the greatest hemolysis in RBC, elicited the greatest IL-1β response in AM and mexAM, and produced the most LMP in mexAM. The Ni@NiO@Ni(OH)2 nanoparticle released the most Ni2+ and caused profound reductions in AM cell viability but failed to cause RBC hemolysis or LMP. Pure NiO nanoparticles exhibited minimal bioactivity and low Ni2+ release. Surface modification with (-COOH) or (-CH3) effectively reduced bioactivity in LMP-mediated inflammation but had minimal effect on Ni2+-driven toxicity. This study reveals that Ni-X NP bioactivity depends on both core composition and surface chemistry, and that surface functionalization reduces inflammation only when lysosomal damage is the primary driver. These findings underscore the need for careful design and evaluation of engineered nanomaterials.
Kendall et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: